Category Archives: News and Events

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 ...

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase ...

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, ...

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ...

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study ...

BriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell’s Bria-OTS+(TM) Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing ...

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+(TM) in Prostate Cancer

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+ TM clinical supply ...

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+(TM) for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...